CoreValve Evolut-R TAVR (26mm) via Percutaneous Femoral Access – Aug 2015

An 88 year-old female presented with progressive shortness of breath – NYHA class III, with a history of hypertension, chronic diastolic HF, COPD and s/p BAV on 7/2/15. TTE revealed severe AS, peak/mean aortic gradient = 65/44 mmHg, AVA = 0.6 sq cm, aortic peak velocity = 4 m/sec and LVEF 65%. CT angio showed minimum diameters of 0.4 x 0.7 cm for right and 0.6 x 0.6 cm for the left common femoral arteries and aortic annulus of 2.5 x 2.1 cm (average 2.3). The STS risk mortality is 5.15 and the Logistic Euroscore mortality is 12.81. Patient was determined to be extreme risk for surgical AVR due to advanced age and marked, generalized frailty. Patient is now planned for CoreValve Evolut R TAVR (26mm) via percutaneous femoral access under conscious sedation.




Leave a Reply

Your email address will not be published.*

Yes, I would like to receive emails from Mount Sinai Hospital. Sign me up!

By submitting this form, you are consenting to receive marketing emails from: Mount Sinai Hospital, One Gustave L. Levy Place, Box, New York, NY, 10029, You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact